首页> 中文期刊>现代肿瘤医学 >HER-2过表达型乳腺癌的分子生物学基础及治疗进展

HER-2过表达型乳腺癌的分子生物学基础及治疗进展

     

摘要

Breast cancer is a a kind of highly heterogeneous malignant tumor by hormone receptor regulation.Different molecular subtypes of disease-free survival,recurrence rate and prognosis are not the same.Patients with HER-2-overexpressing breast cancer diagnosis often experience A higher malignant degree,low survival rate and inferior prognosis,The humanized monoclonal antibody trastuzumab is currently the foundation of treatment for HER-2-overexpressing breast cancer.However,due to drug resistance,targeting low efficiency,breast cancer eventually relapse inevitable.The follow-up treatment after trastuzumab resistant become a new hotspot.This article describes the basis of the molecular biology of HER-2-overexpressing breast cancer and corresponding signal transduction pathways,and as a basis for the development of a series of new drugs.%乳腺癌是一类受激素受体调控且高度异质性的恶性肿瘤,不同类型乳腺癌无病生存期、复发转移率及预后均不相同.其中HER-2过表达型乳腺癌恶性程度高、生存率低,预后相对较差.但却是曲妥珠单抗进行分子靶向治疗的较好的适应症,可极大的改善该类患者的生存率.但由于药物耐药性、靶向效率低等,乳腺癌的最终复发不可避免.针对曲妥珠单抗耐药以后的后续治疗成为新的研究热点,本文介绍了HER-2过表达型乳腺癌发生的分子生物学基础及相应的信号传导过程,及以此为基础开发了一系列新药.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号